Genomic, Epigenomic, and Transcriptomic Profiling towards Identifying Omics Features and Specific Biomarkers That Distinguish Uterine Leiomyosarcoma and Leiomyoma at Molecular Levels

Table 1

Clinical features of nine samples analyzed in this study.

Sample	Clinical diagnosis	Tissue-type obtained	Age	Major axis of tumor (cm)	Preoperative therapy
NM1	Cervical cancer, stage Ib1	Normal myometrium	43	—	None
NM2	Cervical cancer, stage Ib2	Normal myometrium	38	—	None
NM3	Cervical cancer, stage Ib2	Normal myometrium	49	—	None
LM1	Interstitial myoma	Leiomyoma	52	18	None
LM2	Submucosal myoma	Leiomyoma	48	6	None
LM3	Submucosal myoma	Leiomyoma	53	6	GnRHa
LMS1	Leiomyosarcoma, stage IV	Leiomyosarcoma	49	25	None
LMS2	Leiomyosarcoma, stage I	Leiomyosarcoma	54	20	None
LMS3	Leiomyosarcoma, stage I	Leiomyosarcoma	83	10	None

GnRHa, gonadotrophin-releasing hormone analogues.